Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cannabis company, Adastra Labs (XTRX) has submitted its federal sales licence amendment to Health Canada for approval
  • The company’s submission package is based on the extraction, formulation, and manufacture of vaporiser cartridges
  • Adastra has already manufactured over 30,000 vaporiser cartridges for Canada’s adult recreational cannabis market
  • The licence amendment will allow Adastra to offer customers a wider variety of services, and to fill increasing capacities
  • Adastra Labs (XTRX) remains unchanged and is currently trading at C$0.78 per share

Cannabis company, Adastra Labs (XTRX) has submitted its federal sales licence amendment to Health Canada for approval.

The major foundation for Adastra’s sales licence submission package is the company’s extraction, formulation, and manufacturing of vaporiser cartridges. The company has already manufactured tens of thousands of vaporiser cartridges for the Canadian adult recreational cannabis market.

Currently, Adastra can provide B2B client white-labelling services for multiple distillate-related products. These include bulk distillate, and Cannabis 2.0 products like tinctures, vaporisers, and formulations for beverages and edibles. 

If Health Canada approves the federal sales licence amendment, Adastra will be able to broaden its offering to its customers. It will also allow the company to meet increasing capacities which are drawing closer.

Adastra Labs’ CEO, Andy Hale, commented on the company’s latest submission to Health Canada.

“This is a significant milestone for Adastra as we increase production.

“While our B2B orders are filling our capacity, upon approval, the sales licence will allow us to offer a wider range of services to our clients and fill the increased capacity we are bringing online in the near future,” he said.

Adastra’s Director of Production, Dr Kyle Boniface, also elaborated on the importance of this recent development.

“The submission of the sales licence amendment is significant, as it represents the successful operationalisation of Adastra’s extraction, formulation, and product manufacturing capabilities.

“In our initial operations, Adastra has extracted over 1,700 kilograms of biomass, and manufactured over 30,000 vaporiser cartridges destined for the adult recreational market in Canada,” he said.

Adastra Labs (XTRX) remains unchanged and is trading at C$0.78 per share at 10:52am EDT.

More From The Market Herald

Shiny Health appoints interim CEO after Nadeau’s resignation

Shiny Health & Wellness has appointed Meris Kott as the cannabis company's interim CEO after the resignation of Michael Nadeau.

The Market Herald’s Weekly Cannabis Report – Nov. 24, 2023

This week's cannabis stock news includes Shiny Health & Wellness appointing Meris Kott as its interim CEO after Michael Nadeau resigned.

Buzz on the Bullboards: More stocks to be thankful for

Cannabis, resource and industrial sectors were busy in fall stock markets, and traders are focusing on value heading into the holidays.
biosteel

Canopy Growth notches court-approved sale of BioSteel

Canopy Growth (TSX:WEED) announces it has received a court-approved sale of its BioSteel sports drink subsidiary.